secwatch.observer — SEC 8-K summary
======================================

Issuer:     LIPELLA PHARMACEUTICALS INC. (LIPO)
CIK:        0001347242
Form:       8-K
Filed at:   2025-03-11T23:59:59+00:00
Accession:  0001753926-25-000425
Event type: other_material
Sentiment:  neutral
Materiality: 0.50
Item codes: 1.01, 3.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Lipella raises $726k in fourth closing of Series B preferred offering at $2.51 conversion
--------------------------------------------------------------------------------

- Gross proceeds of $726,000 from sale of 7,260 Series B shares convertible into 289,241 common shares at $2.51/share.
- Net proceeds of $602,580; Spartan Capital received $123,420 in fees, 84,700 Series C voting preferred shares and warrants for 28,924 common shares.
- CEO Jonathan Kaufman granted irrevocable voting power over Spartan's issued shares via proxy.
- Proceeds from the offering to be used for working capital and general corporate purposes.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000425/0001753926-25-000425-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1347242/000175392625000425/g084727_8k.htm
  HTML page:      https://secwatch.observer/filing/0001753926-25-000425

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer